WO2023170608 - ACTIVATORS OF EFFECTOR T CELLS
National phase entry:
Publication Number
WO/2023/170608
Publication Date
14.09.2023
International Application No.
PCT/IB2023/052217
International Filing Date
08.03.2023
Title **
[English]
ACTIVATORS OF EFFECTOR T CELLS
[French]
ACTIVATEURS DE LYMPHOCYTES T EFFECTEURS
Applicants **
ORUM THERAPEUTICS, INC.
Inventors
PARK, Peter U.
FISHKIN, Nathan
BAI, Chen
TAKROURI, Khuloud
RIBKOVSKAIA, Zinaida
PALACINO, James Joseph
WONG, Wesley
SKALETSKAYA, Anna
NAMGOONG, Suk
LIM, Joanne Y.H.
Priority Data
63/318,278
09.03.2022
US
63/477,053
23.12.2022
US
63/488,211
03.03.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
MOIP
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 11195 | |
| EPO | Filing, Examination, Granting | 121789 | |
| Japan | Filing, Examination, Granting | 4833 | |
| South Korea | Filing, Examination, Granting | 5593 | |
| USA | Filing, Examination, Granting | 34140 |
Total:
177,550
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure provides antibody drug conjugates and methods of delivering the conjugates to effector T cells. Also disclosed are novel Cbl-b inhibitors. The compounds and conjugates are useful for treating diseases in subjects in need thereof.[French]
La présente invention concerne des conjugués anticorps-médicament et des procédés d'administration des conjugués à des lymphocytes T effecteurs. L'invention concerne également de nouveaux inhibiteurs de Cbl-b. Les composés et les conjugués sont utiles pour le traitement de maladies chez des sujets en ayant besoin.